# PRODUCTION OF POTENT BIOACTIVE COMPOUNDS BY CERTAIN Streptomyces SPECIES

#### BY

# FATIMA HEMAIA MOHAMMED MOTAWE

B.Sc. Agric. Sci. (Biotechnology), Fac. Agric., Cairo Univ., 2004 M.Sc. Agric. Sci. (Agric. Microbiology), Fac. Agric., Cairo Univ., 2010

## **THESIS**

Submitted in Partial Fulfillment of the Requirements for the Degree of

# **DOCTOR OF PHILOSOPHY**

In

Agricultural Sciences (Microbiology)

Department of Agricultural Microbiology
Faculty of Agriculture
Cairo University
EGYPT

2016

### APPROVAL SHEET

# PRODUCTION OF POTENT BIOACTIVE COMPOUNDS BY CERTAIN Streptomyces SPECIES

# Ph.D. Thesis In Agric. Sci. (Agricultural Microbiology)

By

## FATIMA HEMAIA MOHAMMED MOTAWE

B.Sc. Agric. Sci. (Biotechnology), Fac. Agric., Cairo Univ., 2004 M.Sc. Agric. Sci. (Agric. Microbiology), Fac. Agric., Cairo Univ., 2010

# APPROVAL COMMITTEE

Dr. El-SHAHAT MOHAMED RAMADAN  Professor of Agric. Microbiology, Fac. Agric., Ain-Shams University
Dr. MICHAEL R. GOHAR
Professor of Agric. Microbiology, Fac. Agric., Cairo University
Dr. ENSAF IMAM DAWOUD
Professor of Agric. Microbiology, Fac. Agric., Cairo University
Dr. FERIAL MOHAMED RASHAD Professor of Agric. Microbiology, Fac. Agric., Cairo University

Date / 5 / 2016

### SUPERVISION SHEET

# PRODUCTION OF POTENT BIOACTIVE COMPOUNDS BY CERTAIN Streptomyces SPECIES

Ph.D. Thesis
In
Agric. Sci. (Agricultural Microbiology)

By

# FATIMA HEMAIA MOHAMMED MOTAWE

B.Sc. Agric. Sci. (Biotechnology), Fac. Agric., Cairo Univ., 2004 M.Sc. Agric. Sci. (Agric. Microbiology), Fac. Agric., Cairo Univ., 2010

### SUPERVISION COMMITTEE

#### Dr. FERIAL MOHAMED RASHAD

Professor of Agricultural Microbiology, Fac. Agric., Cairo University

### Dr. ENSAF IMAM DAWOUD

Professor of Agricultural Microbiology, Fac. Agric., Cairo University

### Dr. NADIA HASAN TAWFIEK ABD EL- NASSER

Researcher Professor of Microbial Chemistry, National Research Centre, Giza

Name of Candidate: Fatima Hemaia Mohammed Motawe Degree: Ph.D.

**Title of Thesis:** Production Of Potent Bioactive Compounds By Certain

Streptomyces Species

**Supervisors:** Dr. Ferial Mohamed Rashad

Dr. Ensaf Imam Dawoud

Dr. Nadia Hassan Tawfiek Abd- El Nasser

**Department:** Agricultural Microbiology **Approval:** 5 / 5 /2016

#### **ABSTRACT**

Screening, isolation and characterization are still the powerful strategies for searching about potent bioactive compounds of biotechnological importance. Accordingly, from twenty different soil samples collected from different area, 500 actinomycete isolates were recovered and screened for their ability to produce antimicrobial metabolite(s). Only 56 exhibited antimicrobial activities against the tested microorganisms. On the basis of antimicrobial activity, 10 promising isolates that exhibited antagonistic activity against at least one of each of Gram negative, Gram positive and/or filamentous fungi in addition to Candida were selected for further studies. Based on the morphological, cultural, physiological, biochemical and chemotaxonomical characteristics, the numerical identification using the UPGMA program, confirmed that the 10 active strains of Streptomyces were assigned to three hierarchical clusters: first cluster consists of 7 strains, 2<sup>nd</sup> cluster consists of one strain and the 3<sup>rd</sup> cluster consists of two strains. The most potent strains FHM275 and FHM572 exhibited strong inhibitory effects against the tested multidrug resistant nosocomial strains Ethyl acetate: chloroform (1:1) proved to be the best solvent system for extracting their bioactive compound(s) from the cultural filtrates. MIC values of crude bioactive compound(s) produced by FHM275 and FHM572 against the tested microorganisms were generally lower than those obtained by reference antibiotics which indicated their antimicrobial potencies. The bioactive crude extracts from the most potent Streptomycetes FHM275 and FHM572 showed cytotoxic activities against colon cell line HCT116 and lung cell line A549 but crude extract from FHM572 was more effective against lung cell line A549 than that extracted from FHM275. Phylogenetic analysis of the FHM275 and FHM572 strains based on 16S rRNA gene sequences showed highest similarity (99%) with Streptomyces fulvissmus and St. pratensis respectively; they were deposited in the GenBank under the accession numbers of KM438035 and KM046933 respectively. The optimum conditions for maximal productivity of bioactive metabolite(s) by St. fulvissmus FHM275and St. pratensis FHM572 were as follow: 20% v/v loading volume at pH ranged from 7.0 to 7.5, 2% or 1% v/v of 5 or 7- day old spores suspension as inoculum size respectively, incubation at 30°C or 28°C respectively and agitation speed rate of 150 or 180 rpm respectively for 5 days. The highest productivity of bioactive compound(s) was achieved at g/l: starch, 20; KNO<sub>3</sub>, 2.0; (C/N ratio= 28.30) and K<sub>2</sub>HPO<sub>4</sub>, 1.0; CaCO<sub>3</sub>, 3.0; MgSO<sub>4</sub>.7H<sub>2</sub>O<sub>7</sub>, 0.5; NaCl, 0.5 and FeSO<sub>4</sub>.7H<sub>2</sub>O, 0.01. Using the silica gel column chromatography, the crude compound(s) by FHM275 and FHM572 were purified into three or two fractions, respectively. Fraction F2 from FHM275 and fraction FH2 from FHM572 were the major and the most potent against tested microorganisms including nosocomial pathogens. F2 which obtained from the strain FHM275 did not show any damage to the normal cell line up to 100 µg/ml and showed strong activity and highest selectivity against lung carcinoma (IC<sub>90</sub> up to 6.25 μg/ml), good activity against colon cancer (IC<sub>50</sub> of 21. 4 μg/ml). FH2 killed 90% of lung, 50% of breast and colon at 6.25, 11.3 and 14.4 µg/ml, respectively. F2 and FH2 were identified as methyl nonactate or methyl homononactate respectively using spectroscopic techniques (MS, UV, IR, <sup>1</sup>H and <sup>13</sup>C NMR).

**Key words:** *Streptomyces* spp., Antimicrobial activity, Cytotoxic activity, Methyl nonactate, Methyl homononactate, Numerical taxonomy, 16S rRNA, Structure elucidation.

# **DEDICATION**

This Thesis is dedicated to my dear parents: To my father, for his help, patience, continuous encouragement and support; to my mother, for her deep prayers, continuous care and love.

Also I dedicate this work to my dear brothers and beloved twin sister for their love and help.

# ACKNOWLEDGEMENT

In the name of GOD, most gracious, most merciful. All praises be to GOD, the cherisher and sustainer of the world .... ALLAH.

I wish to express my deepest thanks and gratitude to **Dr. Ferial M. Rashad** Professor of Agricultural Microbiology, Cairo University for her kind supervision, assistance, encouragement, patience, continuous guidance, writing the manuscript and for her sympathy and motherly feeling. Her sincere supervision, unlimited assistance and valuable discussion during all stages of fulfillment of the thesis are deeply appreciated.

I also would like to thank **Dr.** Ensaf I. Dawoud Professor of Agricultural Microbiology, Cairo University for her assistance, encouragement, support, sincere advices and helpful supervision.

I wish to express my grateful and sincere thanks to Dr. Nadia H. Abd El Nasser Researcher Professor of Microbial Chemistry, NRC, Giza for suggesting the problem, her great support, continuous guidance, as well as, for her invaluable advices, ideas and helpful supervision.

Thanks are also extended to **Dr.** Amal M. Ali Researcher Professor of Microbial Chemistry, NRC, Giza for her supervision, guidance, assistance and support.

I would like to thank my father Dr. Hemaia M. Motawe, Researcher Professor of Phytochemistry, NRC, Giza for his continuous help, assistance and interpretation of spectral data and structure elucidation of isolated compounds.

I would like to express my thanks to Dr. Khaled Mahmoud Mohamed, Head of Bioassay—Cell Culture Laboratory, NRC, Giza, for his kind help and assistance. My endless thanks to my colleagues, Dr. Hayam M. Fathy, Mrs. Ayatollah Samir El-Zayat, and Mr. Bahieelden E. Aly, Microbiology Dept., Faculty of Agriculture, Cairo University; for their cooperation, assistance, great and continuous help, great thanks to everyone who offered me help and assistance.

# **CONTENTS**

INTRODUCTION	
REVIEW OF LITERATURE	
1. Microbial bioactive secondary metabolites	
2. Soil as a source of microbial bioactive secondary	
metabolites	
3. Bioactive compounds produced by actinomycetes	
<b>4.</b> Bioactive compounds produced by <i>Streptomyces</i>	
<b>b.</b> Antitumor/antibiotics	
5. Secondary metabolite biosynthesis	
a. Nonribosomal peptides (NRPs)	
<b>b.</b> Polyketides (PKs)	
6. Factors affecting the production of secondary	
metabolites	
<b>a.</b> Carbon source regulation	
<b>b.</b> Nitrogen source regulation	••••
c. Phosphate regulation	
d. Minerals	
e. Inoculum age and size	
<b>f.</b> Fermentation time	
g. Temperature	
h. Agitation and aeration	
i. pH	
7. Characteristics of Streptomycetes	
MATERIALS AND METHODS	
1. Sample collection	
2. Isolation of actinomycete colonies from soil samples	
3. Maintenance of streptomycete isolates	
4. Preliminary screening for antimicrobial activity	
5. Characterization of the most active isolates	
<b>a.</b> Morphological characterization of the selected isolates	

1.	Spore chain morphology
2. 3	Spore surface ornamentation
]	• Cultural characteristics
	<b>1.</b> Color of the spore mass
	2. Color of substrate mycelium (reverse color)
	<b>3.</b> Diffusible pigments
(	c. Physiological and biochemical properties
	<b>1.</b> Utilization of different carbon sources
	2. Melanin pigment production
	<b>3.</b> Detection of different enzyme activities
(	d. Chemotaxonomical characteristics
	1. Cell wall analysis
	2. Whole- cell sugars
	e. Numerical identification of active streptomycete isolates.
<b>6.</b> ]	Extraction of the bioactive compound(s) from potent
(	cultures filtrates
<b>7</b> 1	Determination of Minimum Inhibition Concentration
/ • J	
(	(MIC)
(	MIC) Antimicrobial activity of the selected bioactive isolates
8. <i>.</i>	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens
8. 2	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8 3 9	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 2 3. 3 9. 2	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 2 8. 3 9. 2 9. b	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 2 3. 3 9. 2 a b	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  Human normal and tumor cell lines and cell cultures.  Cytotoxic activity.  Molecular identification.
8. 1 8. 2 9. 1 a b	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 2 8. 3 9. 3 9. 3 b	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  In the Human normal and tumor cell lines and cell cultures.  In Cytotoxic activity.  Molecular identification.  a. Preparation of template DNA.  b. PCR amplification.
8. 1 8. 2 9. 1 a b	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 1 8. 2 9. 1 a b	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  In unique the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  In vitro cy
8. 4 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 4 3 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  In unitro cytotoxic activities bioassay.  In cytotoxic activity.  Molecular identification.  In a. Preparation of template DNA.  In the product of PCR amplification.  In the products.  In the pathogen is of the amplified PCR product.  In the pathogen is of the pathog
8. 4 3 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 4 3 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  In uniformal and tumor cell lines and cell cultures.  In cytotoxic activity.  Molecular identification.  In a. Preparation of template DNA.  In the b. PCR amplification.  In the conditions are selected bioactive isolates and phylogenetic analysis.  In the cytotoxic activity is product.  In the cytotoxic activity is product is product.  In the cytotoxic activity is product is product.  In the cytotoxic activity is product is product.  In the cytotoxic activities is produ
8. 4 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  Human normal and tumor cell lines and cell cultures.  Cytotoxic activity.  Molecular identification.  a. Preparation of template DNA.  b. PCR amplification.  c. Purification of PCR products.  d. Sequencing of the amplified PCR product.  e. Sequence similarities and phylogenetic analysis.  Optimization of fermentation conditions.  a. Environmental conditions.  1. Seed inoculum age.  2. Fermentation time.
8. 4 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  Human normal and tumor cell lines and cell cultures.  Cytotoxic activity.  Molecular identification.  a. Preparation of template DNA.  b. PCR amplification.  c. Purification of PCR products.  d. Sequencing of the amplified PCR product.  e. Sequence similarities and phylogenetic analysis.  Optimization of fermentation conditions  a. Environmental conditions.  1. Seed inoculum age.  2. Fermentation time.  3. Inoculum size.
8. 4 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs
8. 4 3 9. 7 a b 10.	Antimicrobial activity of the selected bioactive isolates against the multi-drug resistant nosocomial pathogens and MICs.  In vitro cytotoxic activities bioassay.  Human normal and tumor cell lines and cell cultures.  Cytotoxic activity.  Molecular identification.  a. Preparation of template DNA.  b. PCR amplification.  c. Purification of PCR products.  d. Sequencing of the amplified PCR product.  e. Sequence similarities and phylogenetic analysis.  Optimization of fermentation conditions  a. Environmental conditions.  1. Seed inoculum age.  2. Fermentation time.  3. Inoculum size.

<b>7.</b> Medium pH	
<b>b.</b> Nutritional requirements	
1. Carbon source	
2. Nitrogen source	
3. Phosphate source	
<b>4.</b> Effect of different concentrations of CaCO <sub>3</sub>	
<b>5.</b> Effect of different concentrations of MgSO <sub>4</sub>	
<b>6.</b> Effect of different concentrations of FeSO <sub>4</sub>	
7. Effect of different concentrations of NaCl	
12. Separation of the bioactive agent(s) produced by St.	
pratensis FHM572 and St. fulvissimus FHM275	
13. Physicochemical characteristics of crude bioactive	
compound(s) produced by St. pratensis FHM572 and	
St. fulvissimus FHM275	
14. Purification of crude bioactive compound(s) produce	
by St. fulvissimus FHM275 and St. pratensis FHM572	
a. Thin Layer Chromatography (TLC)	
<b>b.</b> Silica Column Chromatography	
15. Structure elucidation of purified bioactive compound	
a. Mass spectrum	
<b>b.</b> The ultraviolet and Fourier transform infrared spectra	
c. Nuclear Magnetic Resonance (NMR)	
16. Statistical analysis	
17. Media and solutions	
RESULLTS	
1. Isolation of Streptomycetes and preliminary screening	
for antimicrobial activity	
2. General characteristics of selected isolates	
a. Micro-morphological characteristics	
<b>b.</b> Macro-morphological characteristics (Cultural	
characteristics)	
c. Physiological and biochemical features	
<b>d.</b> Chemotaxonomical characters	
3. Numerical identification of Streptomyces isolates	
4. Extraction of the bioactive compound(s) from potent	
culture filtrates	
5. Minimum Inhibition Concentration (MIC)	
6. Antimicrobial activity against the multi-drug resistant	
nosocomial pathogens and MICs	

7. In vitro cytotoxic activities against human tumor cell
lines
Molecular identification of the selected potent isolates
Optimization of the fermentation conditions for
production of bioactive compound(s) by the selected
isolates
a. Environmental factors
1. Effect of seed inoculum age
<b>2.</b> Effect of fermentation time
<b>3.</b> Effect of inoculum size
<b>4.</b> Effect of incubation temperature
<b>5.</b> Effect of pH
<b>6.</b> Effect of working volume
<b>7.</b> Effect of shaking speed
<b>b.</b> Nutritional requirements
1. Effect of carbon sources
<b>2.</b> Effect of different nitrogen sources
<b>3.</b> Effect of different phosphate sources
<b>4.</b> Effect of different concentrations of calcium carbonate
<b>5.</b> Effect of different concentrations of magnesium sulfate
<b>6.</b> Effect of different concentrations of sodium chloride
<b>7.</b> Effect of different concentrations of ferrous sulfate
Physicochemical properties of crude bioactive
compounds
Purification of bioactive compounds
<b>a.</b> bioactive compound(s) produced by <i>St. fulvissimus</i>
FHM275
<b>b.</b> bioactive compound(s) produced by <i>St. pratensis</i>
FHM275
Antibacterial activities of separated fractions
. Cytotoxic activities of separated fractions
. Structure elucidation of purified bioactive compounds
SCUSSION
ONCLUSION
UMMARY
EFERENCES
PPENDIX
RABIC SUMMARY

# LIST OF TABLES

<b>No.</b> 1.	Title The characteristics of the classical antibiotics produced by Streptomyces spp	P
2.	Sources of test organisms used	
3.	Antibiotic sensitivity profile of nosocomial multi-resistant strains.	
4.	Treatments for determination of the best carbon source	
5.	Treatments for determination of the best nitrogen source	
6.	Treatments for determination of the best phosphate sources	
7.	Cultural features of potent bioactive streptomycete isolates	
8.	Streptomycete isolates identified as <i>Streptomyces</i> species following the keys of Szabo <i>et al.</i> (1975) and Holt <i>et al.</i> (1994)	
9.	The antimicrobial activity of bioactive compound(s) extract by different solvents from crude filtrate of isolate HM275	
10.	The antimicrobial activity of bioactive compound(s) extract by different solvents from crude filtrate of isolate HM572	
11.	MIC values of bioactive crude extracts from cultural filtrate of isolates Streptomyces FHM275 and Streptomyces FHM572	

12.	Antimicrobial activity of the selected Streptomycete strains FHM275 and FHM572 against multi-drug resistant nosocomial pathogens	78
13.	MIC values of bioactive crude extracts from cultural filtrates of isolates FHM275 and <i>Streptomyces</i> FHM572	78
14.	Cytotoxic activities of the crude extracts from Streptomycetes isolates FHM275 and FHM572	80
15.	Selectivity index (SI) of the cytotoxic crude extracts from Streptomycetes isolates	81
16.	Rf values of bioactive compounds produced by <i>St. fulvissimus</i> FHM275 and <i>St. pratensis</i> FHM572 in different solvent systems	107
17.	R <sub>f</sub> values of purified bioactive compounds produced by St. fulvissimus FHM275 and St. pratensis FHM572 in different solvent systems	111
18.	Cytotoxic activities and selectivity index (SI) of the crude extract and purified compound from <i>St. fulvissimus</i> FHM275	113
19.	Cytotoxic activities and selectivity index (SI) of the crude extract and purified compound from <i>St. pratensis</i> FHM572	113
20.	<sup>1</sup> H NMR and <sup>13</sup> C of bioactive compounds F2, FH2	124
21.	Short characterization of selected potent <i>Streptomyces</i> strains	151
		1.7.1

# LIST OF FIGURES

No.	Title	Page
1.	Distribution of active actinomycete isolates against different groups of tested microorganisms	65
2.	Percentage of active actinomycete isolates against the different tested microorganisms and the range of inhibition zone in mm diameter	65
3.	Antimicrobial activity of the selected bioactive isolates against different microbial groups: (a) Gram positive bacteria, (b) Gram negative bacteria and (c) fungi	66
4.	Photomicrographs showing sporphore types of potent isolates	68
5.	Photomicrograph showing spore surface ornamentation :a) smooth spore surface of isolates Nos. FHM2, FHM26, FHM28, FHM120, FHM274, FHM275, FHM276, FHM572 and FHM578 (25,000 ×), b) hairy spore surface of isolate No. FHM1	69
6.	Physiological and biochemical properties of the selected isolates	71
7a.	Photograph showing whole cell diaminopimelic acid (DAP) of the selected 10 bioactive isolates: LL-DAP (L) and meso-DAP (M); control (C)	72
7b.	Photograph showing whole cell sugars of the selected 10 bioactiveisolates: controls(C),galactose(ga), arabinose(a), xylose (x), glucose (g), mannose (m), ribose (ri) and rhamnose (rh)	72

8.	Dendrogram derived from UPGMA cluster analysis of phenotypic characters showing the relationships between 10 strains of <i>Streptomyces</i> isolated from different Egyptian soils	74
9.	Cytotoxicity assays of the crude extracts from Streptomycete isolates FHM275 and FHM572 against human caucasian breast adenocarcinoma (MCF 7), colon cell line (HCT 116), human hepatocellular carcinoma cell line (HePG 2), lung carcinoma cell line (A549) as well as normal human epithelial amnion cells. DOX*: Doxorubicin (adriamycin) reference antitumor drug; IC50: Inhibition concentration of the sample which causes the death of 50% of cells in 48 hr; IC90: inhibition concentration of the sample which causes the death of 90% of cells in 48 h	80
10.	Phylogenetic tree based on partial 16S rDNA sequences showing the relationship of <i>St. fulvissmus</i> FHM275 and <i>St. pratensis</i> FHM572 with other species belonging to the genus <i>Streptomyces</i>	82
11.	Effect of seed inoculum age on production of the bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = 2.13; and b) <i>St. pratensis</i> FHM572, LSD <sub>0.01</sub> value = 2.14	84
12.	Effect of fermentation time on production of the bioactive compounds by: a) $St.$ fulvissimus FHM275, $D_{0.01}$ value = 1.90; and b) $St.$ pratensis FHM572, $LSD_{0.01}$ value = 2.01	85
13.	Effect of inoculum size on production of the bioactive compounds by: a) $St.$ fulvissimus FHM275, LSD <sub>0.01</sub> value = 2.15 and b) $St.$ pratensis FHM572, LSD <sub>0.01</sub> value = 2.13	87
14.	Effect of incubation temperature on production of the bioactive compounds by: a) $St.$ $fulvissimus$ FHM275, $LSD_{0.01}$ value = 2.15 and b) $St.$ $pratensis$ FHM572, $LSD_{0.01}$ value = 2.14	88

15.	Effect of pHs on production of the bioactive compounds by: a) $St$ . $fulvissimus$ FHM275, LSD <sub>0.01</sub> value = 2.0; and b) $St$ . $pratensis$	00
16.	572FHM572, LSD <sub>0.01</sub> value = 2.13 Effect of working volume on production of the bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = 2.17; and b) <i>St.</i>	89
17.	pratensis FHM572, LSD <sub>0.01</sub> value = $2.15$ Effect of shaking speed on production of the bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = $2.14$ ; and b) <i>St.</i>	91
	<i>pratensis</i> FHM572, LSD <sub>0.01</sub> value = 2.15	92
18.	Effect of different carbon sources on production of the bioactive compounds by: a) $St.$ fulvissimus FHM275, LSD <sub>0.01</sub> value = 1.83; and b) $St.$ pratensis FHM572, LSD <sub>0.01</sub> value = 1.79	94
19.	Effect of different concentrations of starch on production of the bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = $2.14$ ; and b) <i>St. pratensis</i> FHM572, LSD <sub>0.01</sub> value = $2.62$	96
20.	Effect of different nitrogen sources on production of the bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = $2.12$ ; and b) <i>St. pratensis</i> FHM572, LSD <sub>0.01</sub> value = $2.12$	97
21.	Effect of different concentrations of potassium nitrate on production of the bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = 2.14; and b) <i>St. pratensis</i> FHM572, LSD <sub>0.01</sub> value = 2.13	98
22.	Effect of different phosphate sources on the production of bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = 2.14; and b) <i>St. pratensis</i> FHM572, LSD <sub>0.01</sub> value = 2.13	100
23.	Effect of different K2HPO4 concentrations on production of the bioactive compounds by: a) <i>St. fulvissimus</i> FHM275, LSD <sub>0.01</sub> value = 2.14; and b) <i>St. pratensis</i> FHM572, LSD <sub>0.01</sub> value = 2.13	101